Corient Private Wealth LLC Increases Stake in Medpace Holdings, Inc. $MEDP

Corient Private Wealth LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 47.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,409 shares of the company’s stock after buying an additional 1,415 shares during the period. Corient Private Wealth LLC’s holdings in Medpace were worth $1,384,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MEDP. Wasatch Advisors LP increased its holdings in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the period. Mawer Investment Management Ltd. boosted its stake in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares in the last quarter. AQR Capital Management LLC grew its stake in Medpace by 15.1% during the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after buying an additional 81,637 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Medpace by 15.6% during the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after acquiring an additional 61,764 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its position in shares of Medpace by 11.4% in the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after acquiring an additional 45,435 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent analyst reports. Barclays increased their target price on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Rothschild Redb cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Robert W. Baird set a $613.00 target price on shares of Medpace in a research note on Friday, October 24th. BMO Capital Markets started coverage on shares of Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price on the stock. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus target price of $490.82.

Insider Buying and Selling

In related news, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 387,925 shares of company stock worth $233,386,647 in the last three months. 20.30% of the stock is currently owned by insiders.

Medpace Price Performance

Shares of Medpace stock opened at $572.00 on Thursday. The company has a market capitalization of $16.11 billion, a PE ratio of 40.00, a P/E/G ratio of 2.15 and a beta of 1.43. The business has a 50-day moving average of $577.81 and a 200-day moving average of $477.65. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.